SG biotech firm Cerecin scores $40m from Korean investors, hints at listing

Cerecin, a Singapore-based biotech developer that specialises in neurotherapeutics, has announced raising $40 million in a funding round backed by South Korean investors.

The investors in Cerecin’s Series IIA funding round include lead investor SK Securities, Hana Financial Investment, Partners Investment, Arche Investment, and K&T Investment.

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief
Subscribe to Newsletter